Ulysses Management Boosted Its Macerich Co (MAC) Holding; Vertex Pharmaceuticals (VRTX) Shareholder Perceptive Advisors Lowered Its Position

February 21, 2018 - By Marguerite Chambers

Joshua Nash increased its stake in Macerich Co (MAC) by 265% based on its latest 2017Q3 regulatory filing with the SEC. Ulysses Management Llc bought 265,000 shares as the company’s stock declined 10.63% while stock markets rallied. The hedge fund run by Joshua Nash held 365,000 shares of the real estate investment trusts company at the end of 2017Q3, valued at $20.06 million, up from 100,000 at the end of the previous reported quarter. Ulysses Management Llc who had been investing in Macerich Co for a number of months, seems to be bullish on the $8.97 billion market cap company. The stock decreased 0.90% or $0.54 during the last trading session, reaching $59.38. About 1.12 million shares traded. Macerich Company (NYSE:MAC) has declined 18.62% since February 21, 2017 and is downtrending. It has underperformed by 35.32% the S&P500.

Joseph Edelman decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 50.02% based on its latest 2017Q3 regulatory filing with the SEC. Perceptive Advisors Llc sold 138,726 shares as the company’s stock rose 33.61% with the market. The hedge fund run by Joseph Edelman held 138,626 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $21.08M, down from 277,352 at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Vertex Pharmaceuticals Inc for a number of months, seems to be less bullish one the $40.87B market cap company. The stock increased 0.16% or $0.26 during the last trading session, reaching $160.98. About 1.14M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 21, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Ulysses Management Llc, which manages about $1.47B and $919.89M US Long portfolio, decreased its stake in Ishares Tr (Put) (IWM) by 300,000 shares to 400,000 shares, valued at $59.27M in 2017Q3, according to the filing. It also reduced its holding in Iac Interactivecorp (NASDAQ:IACI) by 78,752 shares in the quarter, leaving it with 199,622 shares, and cut its stake in Match Group Inc.

Investors sentiment increased to 0.95 in 2017 Q3. Its up 0.17, from 0.78 in 2017Q2. It increased, as 19 investors sold MAC shares while 114 reduced holdings. 39 funds opened positions while 87 raised stakes. 134.98 million shares or 0.62% more from 134.15 million shares in 2017Q2 were reported. Franklin Resource holds 0% or 57,521 shares. Grassi Investment stated it has 0.06% of its portfolio in Macerich Company (NYSE:MAC). D E Shaw reported 0% in Macerich Company (NYSE:MAC). Gateway Investment Advisers Limited reported 7,858 shares. Goldman Sachs Gp reported 0.01% of its portfolio in Macerich Company (NYSE:MAC). Robeco Institutional Asset Mngmt Bv stated it has 105,785 shares or 0.04% of all its holdings. V3 Management Limited Partnership holds 1.54 million shares. Washington Tru Fincl Bank accumulated 91 shares. Huntington Bancorp owns 447 shares. Guardian Life Insurance Of America reported 246 shares. Manning And Napier Limited Liability Corp reported 31,685 shares. First Manhattan Co accumulated 107,725 shares. Point72 Asia (Hong Kong) Ltd invested in 860 shares. Federated Invsts Pa has 0% invested in Macerich Company (NYSE:MAC) for 2,480 shares. Moreover, Old Mutual Customised Solutions (Proprietary) Limited has 0.05% invested in Macerich Company (NYSE:MAC).

Among 23 analysts covering The Macerich Company (NYSE:MAC), 8 have Buy rating, 2 Sell and 13 Hold. Therefore 35% are positive. The Macerich Company had 59 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Evercore given on Monday, December 11. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, June 7 report. On Sunday, August 27 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. Boenning & Scattergood maintained the shares of MAC in report on Wednesday, February 7 with “Buy” rating. The stock has “Neutral” rating by Boenning & Scattergood on Wednesday, April 6. The stock of Macerich Company (NYSE:MAC) has “Buy” rating given on Wednesday, August 9 by RBC Capital Markets. The stock has “Hold” rating by Boenning & Scattergood on Friday, August 4. Evercore upgraded Macerich Company (NYSE:MAC) on Friday, January 26 to “Hold” rating. The firm earned “Outperform” rating on Tuesday, December 19 by Wells Fargo. The stock of Macerich Company (NYSE:MAC) earned “Buy” rating by Zacks on Thursday, September 17.

Perceptive Advisors Llc, which manages about $2.09 billion and $2.62B US Long portfolio, upped its stake in Iovance Biotherapeutics Inc by 363,000 shares to 4.73 million shares, valued at $36.63M in 2017Q3, according to the filing. It also increased its holding in Avexis Inc by 400,000 shares in the quarter, for a total of 671,181 shares, and has risen its stake in Aldeyra Therapeutics Inc (NASDAQ:ALDX).

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 96 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Thursday, February 1 by Leerink Swann. The company was upgraded on Friday, June 23 by Needham. Jefferies maintained the stock with “Buy” rating in Monday, September 25 report. Vetr upgraded the stock to “Hold” rating in Monday, August 17 report. The company was maintained on Wednesday, January 31 by Jefferies. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Tuesday, August 1 by Cowen & Co. The rating was maintained by Jefferies on Thursday, September 29 with “Buy”. The company was initiated on Wednesday, January 20 by Credit Suisse. The firm has “Buy” rating given on Wednesday, July 19 by Jefferies. As per Tuesday, December 12, the company rating was maintained by JMP Securities.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on April, 26. They expect $0.27 earnings per share, up 107.69% or $0.14 from last year’s $0.13 per share. VRTX’s profit will be $68.55M for 149.06 P/E if the $0.27 EPS becomes a reality. After $0.32 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It improved, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. 309,543 were reported by Bancorp Of Montreal Can. The New York-based Pointstate Ltd Partnership has invested 0.61% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Northcoast Asset Mgmt stated it has 4,470 shares. Secor Advisors L P, New York-based fund reported 4,554 shares. Lombard Odier Asset Mgmt (Europe) has invested 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Janney Montgomery Scott Limited Liability Corp reported 0.05% stake. State Board Of Administration Of Florida Retirement System stated it has 368,645 shares or 0.15% of all its holdings. Reliance Of Delaware, a Delaware-based fund reported 10,782 shares. Welch & Forbes Ltd Com has invested 0.72% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Invesco Limited holds 0.17% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 3.10M shares. C M Bidwell Limited invested in 0% or 10 shares. Next Fincl Gp holds 0% or 66 shares. State Street Corp accumulated 11.22M shares or 0.15% of the stock. Manning Napier Advsr Limited Liability Company owns 885,868 shares. Natixis has invested 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Since August 31, 2017, it had 0 buys, and 42 insider sales for $117.74 million activity. Chodakewitz Jeffrey had sold 3,437 shares worth $521,198 on Monday, October 2. Shares for $2.68M were sold by Sachdev Amit on Monday, February 12. The insider ALTSHULER DAVID sold 6,403 shares worth $965,671. MCGLYNN MARGARET G sold $3.25 million worth of stock. 125,000 shares were sold by LEIDEN JEFFREY M, worth $17.67M on Monday, December 11. Parini Michael sold $333,965 worth of stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: